GT
PCVX icon

Glenmede Trust’s Vaxcyte PCVX Stock Holding History

Glenmede Trust’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$252K Buy
6,664
+19
+0.3% +$1.52K ﹤0.01% 1142
2024
Q4 		$544K Sell
6,645
-322
-5% -$32K ﹤0.01% 909
2024
Q3 		$796K Sell
6,967
-5,052
-42% -$455K ﹤0.01% 797
2024
Q2 		$908K Buy
12,019
+158
+1% +$10.8K ﹤0.01% 714
2024
Q1 		$810K Sell
11,861
-3,659
-24% -$253K ﹤0.01% 766
2023
Q4 		$975K Buy
15,520
+582
+4% +$30.2K 0.01% 695
2023
Q3 		$762K Buy
+14,938
New +$737K ﹤0.01% 716

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Glenmede Trust's PCVX Position: Q1 2025 in Review

Glenmede Trust increased its Vaxcyte (PCVX) stake by 0.29% in Q1 2025, buying an estimated $1.52K and bringing the position to 6,664 shares worth $252K. The position accounts for ﹤0.01% of the portfolio, ranked #1142.

Glenmede Trust first reported a position in PCVX in Q3 2023 and has held it in 7 quarters since. The position peaked at $975K in Q4 2023. 315 funds tracked by Wall St. Rank hold PCVX as of Q1 2025.

  • Glenmede Trust held 6,664 shares of Vaxcyte worth $252K as of Q1 2025.
  • Glenmede Trust bought 19 Vaxcyte shares in Q1 2025, an estimated $1.52K.
  • Vaxcyte made up ﹤0.01% of Glenmede Trust's portfolio in Q1 2025, its #1142 holding.
  • Glenmede Trust first reported a position in Vaxcyte in Q3 2023 and has held it in 7 quarters since.
  • Glenmede Trust's Vaxcyte position peaked at $975K in Q4 2023.
  • 315 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2025.

Based on Glenmede Trust's 13F filing for Q1 2025, filed 15 May 2025.